NCT06707051View on ClinicalTrials.gov

Effect of Tranexamic Acid and Calcium Dobesilate for Bleeding of Endometrial Origin

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

June 30, 2024

Conditions

Heavy. Mentrual BleedingAbormal utèrine BleedingBleedingUterine BleedingHypersensitivity ResponseGI DisturbanceAgranulocytosisBleeding PatternEndometrialEndometrial Bleeding

Interventions

DRUG

Tranexamic Acid

Group A received Trannexamic Acid 500mg three times a day for 5 days

DRUG

Calcium dobesilate (Doxium)

Group B recieved Cap.Calcium Dobesilate 500mg 3 times a day for 5 days

Trial Locations (1)

57000

Sahiwal teaching Hospital Sahiwal, Sahiwal

All Listed Sponsors

lead

District Headquarters Teaching Hospital Sahiwal

OTHER

NCT06707051 - Effect of Tranexamic Acid and Calcium Dobesilate for Bleeding of Endometrial Origin | Biotech Hunter | Biotech Hunter